Medicalgorithmics has signed a collaboration agreement to conduct a clinical study on the detection of atrial fibrillation following non-cardiac surgeries. The company’s technological solutions, including original AI algorithms and PocketECG devices, will be used in the study. The agreement with the Population Health Research Institute (PHRI), a research unit of Hamilton Health Sciences Corporation and McMaster University in Canada, was signed for 24 months and will cover centers located in Canada and Spain, with the possibility of extending to other countries. This agreement marks the third such contract for the Polish medtech company in the field of clinical research.
The objective of the study, carried out by PHRI, is to detect atrial fibrillation after surgeries not directly related to the heart and circulatory system. As part of the collaboration, PHRI will use 60 PocketECG devices and a platform for EKG result analysis, using artificial intelligence algorithms for diagnosing heart rhythm disorders. Medicalgorithmics will also provide real-time EKG monitoring and notifications about critical events throughout the duration of the study.
“Collaboration in conducting clinical research is a new area of business development for Medicalgorithmics that we are successfully developing globally. The area of cardiac safety in drug testing is particularly promising, but as you can see, we are also successfully establishing cooperation with other studies. Medicalgorithmics is one of the few providers in the world with top-class technology that can support clinical research implementation in this way. This is also due to our presence in many global markets,” says Magdalena Ślusarczyk, Director of Clinical Affairs and Product Implementation at Medicalgorithmics.
In accordance with the company’s development strategy for 2023-26, commercial involvement in clinical research is to be one of the new business avenues for Medicalgorithmics. The signing of the agreement with PHRI means that the Polish medtech company is currently engaged in three such projects. This includes cooperation with Simbec Orion, in which the proper phase of testing a new drug – oral inhibitor CHIT1 (OATD-01) started in the first quarter of this year with approximately 100 patients with active pulmonary sarcoidosis. The company also provides cardiac safety services in the GOAL-HF clinical trial conducted by the Swedish biopharmaceutical company AnaCardio. In both projects, PocketECG heart monitoring devices, along with a diagnostic platform assisted by AI algorithms, are used to enable remote, real-time heart monitoring of patients participating in new substance tests.
Medicalgorithmics is actively engaging in discussions about participation in further international clinical research projects as a provider of cardiac safety services.
Source: https://managerplus.pl/medicalgorithmics-podpisal-umowe-na-badanie-kliniczne-nad-wykrywaniem-migotania-przedsionkow-z-wykorzystaniem-pocketecg-i-ai-71800
